Aminocaproic acid (Aminocaproic acid)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAminocaproic acidAminocaproic acid
Similar drugsTo uncover
  • Aminocaproic acid
    solution d / infusion 
    ALIUM PFK, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
    PLANT MEDSINTEZ, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    Promomed Rus, Open Company     Russia
  • Aminocaproic acid
    solution d / infusion 
    NESVIZH FACTORY OF MEDICAL PREPARATIONS, RUP     Republic of Belarus
  • Aminocaproic acid
    solution d / infusion 
    FIRM MEDPOLIMER, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    Avexima Sibir, OOO     Russia
  • Aminocaproic acid-SOLOfarm
    solution d / infusion 
    GROTEKS, LLC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    Active substance: aminocaproic acid 50 g

    Excipients: sodium chloride 9 g, water for injection up to 1 liter.

    Description:

    clear colorless liquid

    Pharmacotherapeutic group:hemostatic agent, inhibitor of fibrinolysis.
    ATX: & nbsp

    B.02.A.A.01   Aminocaproic acid

    Pharmacodynamics:

    Aminocaproic acid refers to the synthetic analogues of lysine. Inhibits fibrinolysis, competitively saturating lysine-binding receptors, through which plasminogen (plasmin) binds to fibrinogen (fibrin). It inhibits the activating effect of streptokinase, urokinase and tissue kinases on fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, and reduces the permeability of capillaries. Has antiallergic activity, improves the antitoxic function of the liver, inhibits antibody formation.

    Pharmacokinetics:

    With intravenous administration, the effect is manifested after 15-20 minutes. Absorption is high, the time to reach the maximum concentration in the blood plasma (TSmoch) -2 h, half-life (T1 / 2) - 4 hours. It is excreted by the kidneys unchanged (40-60% of the administered amount) after 4 hours.

    If the excretory function of the kidneys is disturbed, the concentration of aminocaproic acid in the blood increases significantly.

    Indications:

    - bleeding (hyperfibrinolysis, hypo- and afibrinogenemia).

    - bleeding during surgical interventions and pathological conditions accompanied by increased fibrinolytic activity of the blood (for neurosurgical, intracavitary, thoracic, gynecological and urological operations, including the prostate gland, lungs, pancreas, tonsillectomy, after dental interventions, in operations using apparatus of artificial circulation)

    - diseases of internal organs with hemorrhagic syndrome

    - premature placental abruption, prolonged retention in the uterine cavity of the dead fetus, complicated abortion

    - to prevent secondary hypofibrinogenemia in massive transfusions of canned blood.

    Contraindications:

    Hypersensitivity to the components of the drug, a tendency to thrombosis and thromboembolic diseases, hypercoagulability (thrombosis, thromboembolism), cerebral circulation disorders, coagulopathy due to diffuse intravascular coagulation (DVS-syndrome), kidney disease with impaired excretory function, hematuria, pregnancy.

    Carefully:

    Hypotension, valvular heart disease, bleeding from the upper urinary tract unknown etiology, liver failure, chronic renal failure (CRF).

    Dosing and Administration:

    Intravenously, drip.

    The daily dose for adults is 5-30 g, for children the maximum daily dose is 18 g / m 2, up to 1 year - 3 g; 2-6 years - 3-6 g; 7-10 years - 6-9 years.

    When the need to achieve a rapid effect (acute gipofibrinogenemia) is administered intravenously to a 100 mL sterile 5% solution of sodium chloride isotonic solution at a rate of 50-60 drops per minute. During the first hour, a dose of 4-5 g is administered, in the case of continuing bleeding - until it stops at 1 g every hour, but not more than 8 hours. With continued bleeding, infusions are repeated every 4 hours.

    Children, from the calculation. 100 mg / kg body weight in the first hour, then 33 mg / kg / h. In acute blood loss: children under 1 year - 6 g, 2-4 years - 6-9 g, 5-8 years - 9-12 g, 9-10 years - 18 g. Duration of treatment - 3-14 days.

    Side effects:

    Dizziness, tinnitus, headache, nausea, diarrhea, nasal congestion, skin rash, reduced blood pressure, orthostatic hypotension, seizures, rhabdomyolysis, myoglobinuria, acute renal failure, subendocardial haemorrhage.

    Interaction:

    You can combine with the introduction of hydrolysates, glucose solution, anti-shock solutions. In acute fibrinolysis, fibrinogen should additionally be administered in an average daily dose of 2-4 mg (maximum dose of 8 g).

    Anticoagulants of direct and indirect action, antiaggregants reduce the effectiveness of the action of aminocaproic acid.

    Form release / dosage:

    Solution for infusions 5%.

    Packaging:

    100 ml in bottles of glass with a capacity of 100 ml.

    Bottle with instructions for use in a pack of cardboard.

    For hospital:

    - 48 bottles without bundles with 5 instructions for use in a box of corrugated cardboard.

    - 1 bottle with instructions for use (from 1 to 48 bottles with an equal number of instructions for use) without a bundle in a box of corrugated cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    4 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002281 / 01
    Date of registration:13.10.2008
    The owner of the registration certificate:KRASFARMA, JSC KRASFARMA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp30.11.2012
    Illustrated instructions
      Instructions
      Up